Top

Published in:

Open Access 01-03-2018 | Original Article

Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2018

Abstract

Purpose

The main objective was to quantify any potential differences in pharmacokinetic (PK) parameters (AUC and C_max) between RTXM83, a proposed rituximab biosimilar, and its reference product, using a population PK model approach.

Methods

Rituximab PK and PD data were obtained from a randomized, double-blind, phase III clinical study (RTXM83-AC-01-11) in patients with diffuse large B-cell lymphoma (DLBCL) that received 375 mg/m² intravenous RTXM83 or its reference product with CHOP regimen, every 3 weeks, for six cycles. Rituximab levels were quantified by Meso Scale Discovery assay. PK analysis was performed using NONMEM 7.3.0. The effect of disease and patient covariates on RXTM83 PK was investigated. Model was evaluated using visual predictive check and non-parametric bootstrap.

Results

In total, 251 DLBCL patients (127 and 124 in RXTM83-CHOP and rituximab-CHOP arms, respectively) and 5341 serum concentrations (2703 for RXTM83 and 2638 for rituximab, respectively) were available for the population PK analysis. The volume of distribution of the central compartment (V₁) and clearance of RXTM83 were estimated at 3.19 L and 12.5 mL/h, respectively. Body surface area allowed to explain the interindividual variability for V₁. A statistical analysis showed that systemic exposure (AUC and C_max) of RTXM83 was similar to rituximab. The 90% confidence intervals for all pairwise comparisons were within the predefined bioequivalence interval of 0.80–1.25. PD similarity of B-cell depletion and recovery was also observed.

Conclusions

The time course of RTXM83 was well characterized by the model developed. The systemic exposure of RTXM83 and its associated variability were similar to those for rituximab reference in DLBCL patients, demonstrating PK similarity. The PD similarity of RTXM83 and rituximab reference product was also demonstrated.

Coleman M, Lammers PE, Ciceri F, Jacobs IA (2016) Role of rituximab and rituximab biosimilars in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk 16(4):175–181. https://doi.org/10.1016/j.clml.2016.01.004 CrossRefPubMed

EMA (2014) Guideline on similar biological medicinal products (CHMP/437/04 Rev 1). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf

FDA (2016) Guidance for industry. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm397017.pdf

FDA (1999) Guidance for industry. Population pharmacokinetics. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072137.pdf

Cuello HA, Segatori VI, Alberto M, Pesce A, Alonso DF, Gabri MR (2016) Comparability of antibody-mediated cell killing activity between a proposed biosimilar RTXM83 and the originator rituximab. BioDrugs 30(3):225–231. https://doi.org/10.1007/s40259-016-0171-8 CrossRefPubMed

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235–242. https://doi.org/10.1056/NEJMoa011795 CrossRefPubMed

Pescovitz MD (2006) Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transpl 6(5 Pt 1):859–866. https://doi.org/10.1111/j.1600-6143.2006.01288.x CrossRef

Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, Fiscella M, Gorovits B, Kirschner S, Moxness M, Parish T, Quarmby V, Smith H, Smith W, Zuckerman LA, Koren E (2008) Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 48(5):1267–1281. https://doi.org/10.1016/j.jpba.2008.09.020 CrossRefPubMed

Beal SL, Boeckmann AJ, Bauer RJ (eds) (1989–2011) NONMEM users guides. Icon development solutions, Ellicott City, Maryland, USA

10.

Lindbom L, Pihlgren P, Jonsson EN (2005) PsN-Toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79(3):241–257. https://doi.org/10.1016/j.cmpb.2005.04.005 CrossRefPubMed

11.

Blasco H, Chatelut E, de Bretagne IB, Congy-Jolivet N, Le Guellec C (2009) Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma. Fundam Clin Pharmacol 23(5):601–608. https://doi.org/10.1111/j.1472-8206.2009.00714.x CrossRefPubMed

12.

Muller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, Wenger M, Nickenig C, Peter N, Lengfelder E, Metzner B, Rixecker T, Zwick C, Pfreundschuh M, Reiser M (2012) The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 119(14):3276–3284. https://doi.org/10.1182/blood-2011-09-380949 CrossRefPubMed

13.

Regazzi MB, Iacona I, Avanzini MA, Arcaini L, Merlini G, Perfetti V, Zaja F, Montagna M, Morra E, Lazzarino M (2005) Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. Ther Drug Monit 27(6):785–792CrossRefPubMed

14.

Mandema JW, Verotta D, Sheiner LB (1992) Building population pharmacokinetic–pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 20(5):511–528CrossRefPubMed

15.

Efron BTR (1993) An introduction to the bootstrap. Chapman and Hall/CRC Press., LondonCrossRef

16.

Brendel K, Comets E, Laffont C, Laveille C, Mentre F (2006) Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res 23(9):2036–2049. https://doi.org/10.1007/s11095-006-9067-5 CrossRefPubMedPubMedCentral

17.

Nguyen TH, Comets E, Mentre F (2012) Extension of NPDE for evaluation of nonlinear mixed effect models in presence of data below the quantification limit with applications to HIV dynamic model. J Pharmacokinet Pharmacodyn 39(5):499–518. https://doi.org/10.1007/s10928-012-9264-2 CrossRefPubMed

18.

Yano Y, Beal SL, Sheiner LB (2001) Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28(2):171–192CrossRefPubMed

19.

FDA (2014) Guidance for Industry. Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs—General Consideration. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM389370.pdf

20.

EMA (2010) Guideline on the investigation of bioequivalence (CHMP/1401/98). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf

21.

Rozman S, Grabnar I, Novakovic S, Mrhar A, Jezersek Novakovic B (2017) Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome. Br J Clin Pharmacol 83(8):1782–1790. https://doi.org/10.1111/bcp.13271 CrossRefPubMedPubMedCentral

22.

Gota V, Karanam A, Rath S, Yadav A, Tembhare P, Subramanian P, Sengar M, Nair R, Menon H (2016) Population pharmacokinetics of Reditux, a biosimilar Rituximab, in diffuse large B-cell lymphoma. Cancer Chemother Pharmacol 78(2):353–359. https://doi.org/10.1007/s00280-016-3083-x CrossRefPubMed

23.

EMA (2016) Truxima—EPAR (EMA/CHMP/75695/2017). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004112/WC500222695.pdf

24.

Smolen JS, Cohen SB, Tony HP, Scheinberg M, Kivitz A, Balanescu A, Gomez-Reino J, Cen L, Zhu P, Shisha T (2017) A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 76(9):1598–1602. https://doi.org/10.1136/annrheumdis-2017-211281 CrossRefPubMedPubMedCentral

25.

EMA (2014) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (EMEA/CHMP/BMWP/42832/2005 Rev1). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf

26.

Ng CM, Bruno R, Combs D, Davies B (2005) Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 45(7):792–801. https://doi.org/10.1177/0091270005277075 CrossRefPubMed

27.

Li J, Zhi J, Wenger M, Valente N, Dmoszynska A, Robak T, Mangat R, Joshi A, Visich J (2012) Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia. J Clin Pharmacol 52(12):1918–1926. https://doi.org/10.1177/0091270011430506 CrossRefPubMed

28.

Mangel J, Buckstein R, Imrie K, Spaner D, Franssen E, Pavlin P, Boudreau A, Pennell N, Combs D, Berinstein NL (2003) Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as ‘in vivo purge’ and consolidative immunotherapy following autologous stem cell transplantation. Ann Oncol 14(5):758–765CrossRefPubMed

29.

Jager U, Fridrik M, Zeitlinger M, Heintel D, Hopfinger G, Burgstaller S, Mannhalter C, Oberaigner W, Porpaczy E, Skrabs C, Einberger C, Drach J, Raderer M, Gaiger A, Putman M, Greil R, Arbeitsgemeinschaft Medikamentose Tumortherapie I (2012) Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica 97(9):1431–1438. https://doi.org/10.3324/haematol.2011.059246 CrossRefPubMedPubMedCentral

30.

Dirks NL, Meibohm B (2010) Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49(10):633–659. https://doi.org/10.2165/11535960-000000000-00000 CrossRefPubMed

31.

Anolik JH, Friedberg JW, Zheng B, Barnard J, Owen T, Cushing E, Kelly J, Milner EC, Fisher RI, Sanz I (2007) B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol 122(2):139–145. https://doi.org/10.1016/j.clim.2006.08.009 CrossRefPubMed

32.

Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T, White T, Wright G, Kwak L, Gress R, Tosato G, Wilson WH (2005) B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 106(3):795–802. https://doi.org/10.1182/blood-2004-08-3198 CrossRefPubMedPubMedCentral

Title: Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach
Publication date: 01-03-2018
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2018
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-018-3524-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

Phase 1 summary of plasma concentration–QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML

Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations

A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202)

S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma

Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs

Docetaxel, cisplatin and S-1 (DCS) combination chemotherapy for gastric cancer patients with peritoneal metastasis: a retrospective study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer